Literature DB >> 20078196

Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients.

Sandra Parra1, Judit Marsillach, Gerard Aragonés, Raúl Beltrán, Manuel Montero, Blai Coll, Bharti Mackness, Michael Mackness, Carlos Alonso-Villaverde, Jorge Joven, Jordi Camps.   

Abstract

BACKGROUND: Oxidative stress is associated with human immunodeficiency virus (HIV) infection. Paraoxonase-1 (PON1) is an antioxidant enzyme that is bound to high-density lipoproteins (HDLs). We evaluated whether PON1 gene haplotypes influence the metabolic disturbances, presence of subclinical atherosclerosis, and virologic outcome associated with the infection.
METHODS: DNA from blood samples collected from 234 HIV-infected patients and 633 healthy control subjects had single-nucleotide polymorphisms of PON1(192), PON1(55), PON1(-162), PON1(-832), PON1(-909), PON1(-1076), and PON1(-1741) analyzed using the Iplex Gold MassArray method. Subsequently, the influence of these single-nucleotide polymorphisms on measured biochemical and clinical variables was assessed.
RESULTS: We observed significant differences in the haplotype distribution between the control subjects and the HIV-infected patients. Haplotype H10 (GTCCGTC) was more prevalent in the HIV-infected patients (6.41% vs 0.64%; P < .001), and haplotype H5 (GACCGTC) was less prevalent in HIV-infected patients (27.7% vs 42.9%; P = .001). In HIV-infected patients, haplotype H7 (AATTCCT) was associated with better CD4(+) cell count recovery, higher levels of HDL cholesterol (P = .048) and apolipoprotein A-I (P = .019), lower levels of triglycerides (P = .004), and lower rates of subclinical arteriosclerosis (P < .001).
CONCLUSIONS: PON1 haplotypes segregate with HIV infection, HDL metabolism, the presence of subclinical atherosclerosis, and CD4(+) cell recovery after treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20078196     DOI: 10.1086/650312

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation.

Authors:  Gerard Aragonès; Anabel García-Heredia; Marta Guardiola; Anna Rull; Raúl Beltrán-Debón; Judit Marsillach; Carlos Alonso-Villaverde; Bharti Mackness; Michael Mackness; Juan Pedro-Botet; Pedro Pardo-Reche; Jorge Joven; Jordi Camps
Journal:  J Lipid Res       Date:  2011-10-14       Impact factor: 5.922

Review 2.  Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease.

Authors:  Pravin Kesarwani; Anuradha K Murali; Amir A Al-Khami; Shikhar Mehrotra
Journal:  Antioxid Redox Signal       Date:  2012-10-15       Impact factor: 8.401

Review 3.  HIV-specific immune dysregulation and atherosclerosis.

Authors:  Markella V Zanni; Steven K Grinspoon
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

4.  Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study.

Authors:  Gerard Aragonès; Marta Guardiola; María Barreda; Judit Marsillach; Raúl Beltrán-Debón; Anna Rull; Bharti Mackness; Michael Mackness; Jorge Joven; Josep M Simó; Jordi Camps
Journal:  J Lipid Res       Date:  2011-02-17       Impact factor: 5.922

5.  Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients.

Authors:  Sandra Parra; Judit Marsillach; Gerard Aragonès; Anna Rull; Raúl Beltrán-Debón; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps
Journal:  Lipids Health Dis       Date:  2010-03-25       Impact factor: 3.876

6.  Paraoxonase-1 status in patients with hereditary hemochromatosis.

Authors:  Nicola Martinelli; Anabel García-Heredia; Helena Roca; Núria Aranda; Victoria Arija; Bharti Mackness; Michael Mackness; Fabiana Busti; Gerard Aragonès; Juan Pedro-Botet; Federica Pedica; Ivana Cataldo; Judit Marsillach; Jorge Joven; Domenico Girelli; Jordi Camps
Journal:  J Lipid Res       Date:  2013-03-06       Impact factor: 5.922

7.  Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria.

Authors:  S Iftimie; A García-Heredia; I Pujol; F Ballester; I Fort-Gallifa; J M Simó; J Joven; J Camps; A Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-22       Impact factor: 3.267

8.  HIV infection induces structural and functional changes in high density lipoproteins.

Authors:  Marc O Siegel; Alison G Borkowska; Larisa Dubrovsky; Mary Roth; Ruth Welti; Afsoon D Roberts; David M Parenti; Gary L Simon; Dmitri Sviridov; Samuel Simmens; Michael Bukrinsky; Michael L Fitzgerald
Journal:  Atherosclerosis       Date:  2015-08-29       Impact factor: 5.162

9.  Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.

Authors:  Gerard Aragonès; Carlos Alonso-Villaverde; Pedro Pardo-Reche; Anna Rull; Raúl Beltrán-Debón; Esther Rodríguez-Gallego; Laura Fernández-Sender; Jordi Camps; Jorge Joven
Journal:  BMC Med Genet       Date:  2011-09-22       Impact factor: 2.103

10.  Human-Phosphate-Binding-Protein inhibits HIV-1 gene transcription and replication.

Authors:  Thomas Cherrier; Mikael Elias; Alicia Jeudy; Guillaume Gotthard; Valentin Le Douce; Houda Hallay; Patrick Masson; Andrea Janossy; Ermanno Candolfi; Olivier Rohr; Eric Chabrière; Christian Schwartz
Journal:  Virol J       Date:  2011-07-15       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.